fda indications for semaglutide Approves Oral as First GLP-1 Pill Weight Loss FDA Clears Semaglutide For Cardiac

Do not discontinue tirzepatide without consulting your healthcare provider

By contrast, retatrutide has no approved brand name and no formulation is approved for any indication anywhere in the world as of June 2026

CMS is proposing a decrease in RVUs for many of the CPT Codes for CY2026 , counteracting the increases gained from a higher CF for all CPT codes

JAMA points out that "these adverse events, although rare, must be considered by patients who are thinking about using the drugs for weight loss because the risk-benefit calculus for this group might differ from that of those who use them for diabetes" [20]

SIDE EFFECTS: No adverse side effects have been reported

doi: 10.1038/ismej.2012.4 54 RussellWRGratzSWDuncanSHHoltropGInceJScobbieLet al